These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 32089480)

  • 1. Prognostic impact of lipoprotein (a) on long-term clinical outcomes in diabetic patients on statin treatment after percutaneous coronary intervention.
    Takahashi N; Dohi T; Funamizu T; Endo H; Wada H; Doi S; Kato Y; Ogita M; Okai I; Iwata H; Okazaki S; Isoda K; Miyauchi K; Shimada K
    J Cardiol; 2020 Jul; 76(1):25-29. PubMed ID: 32089480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Lipoprotein (a) on Long-Term Outcomes in Patients with Coronary Artery Disease Treated with Statin After a First Percutaneous Coronary Intervention.
    Suwa S; Ogita M; Miyauchi K; Sonoda T; Konishi H; Tsuboi S; Wada H; Naito R; Dohi T; Kasai T; Okazaki S; Isoda K; Daida H
    J Atheroscler Thromb; 2017 Nov; 24(11):1125-1131. PubMed ID: 28321012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Lipoprotein(a) on Long-term Outcomes in Patients With Diabetes Mellitus Who Underwent Percutaneous Coronary Intervention.
    Konishi H; Miyauchi K; Shitara J; Endo H; Wada H; Doi S; Naito R; Tsuboi S; Ogita M; Dohi T; Kasai T; Okazaki S; Isoda K; Suwa S; Daida H
    Am J Cardiol; 2016 Dec; 118(12):1781-1785. PubMed ID: 27712648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of gender difference on long-term outcomes of percutaneous coronary intervention for coronary artery disease in patients under statin treatment.
    Wada H; Ogita M; Miyauchi K; Shitara J; Endo H; Doi S; Naito R; Konishi H; Tsuboi S; Dohi T; Kasai T; Tamura H; Okazaki S; Isoda K; Suwa S; Daida H
    Heart Vessels; 2017 Jan; 32(1):16-21. PubMed ID: 27107767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of serum lipoprotein (a) level on coronary plaque progression and cardiovascular events in statin-treated patients with acute coronary syndrome: a yokohama-acs substudy.
    Matsushita K; Hibi K; Komura N; Kimura Y; Matsuzawa Y; Konishi M; Maejima N; Iwahashi N; Kosuge M; Ebina T; Tamura K; Kimura K
    J Cardiol; 2020 Jul; 76(1):66-72. PubMed ID: 32037254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention.
    Konishi H; Miyauchi K; Kasai T; Tsuboi S; Ogita M; Naito R; Sai E; Fukushima Y; Katoh Y; Okai I; Tamura H; Okazaki S; Daida H
    Am J Cardiol; 2015 Jan; 115(2):157-60. PubMed ID: 25476560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of elevated lipoprotein(a) in coronary artery revascularization patients.
    Kwon SW; Lee BK; Hong BK; Kim JY; Choi EY; Sung JM; Rhee JH; Park YM; Ma DW; Chung H; Mun HS; Lee SJ; Park JK; Min PK; Yoon YW; Rim SJ; Kwon HM
    Int J Cardiol; 2013 Sep; 167(5):1990-4. PubMed ID: 22633779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between lipoprotein(a) and revascularization after percutaneous coronary intervention in type 2 diabetes mellitus patients with acute coronary syndrome.
    Hao Y; Yang Y; Wang Y; Li J
    Curr Med Res Opin; 2022 Oct; 38(10):1663-1672. PubMed ID: 35575139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between statin therapy and long-term clinical outcomes in patients with stable coronary disease undergoing percutaneous coronary intervention.
    Wu HP; Yang FC; Lin HD; Cai CZ; Chuang MJ; Chiang KF; Lin MJ
    Sci Rep; 2024 Jun; 14(1):12674. PubMed ID: 38830964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN.
    Puri R; Ballantyne CM; Hoogeveen RC; Shao M; Barter P; Libby P; Chapman MJ; Erbel R; Arsenault BJ; Raichlen JS; Nissen SE; Nicholls SJ
    Atherosclerosis; 2017 Aug; 263():137-144. PubMed ID: 28641153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease.
    Zhu L; Fang Y; Gao B; Jin X; Zheng J; He Y; Huang J
    BMC Cardiovasc Disord; 2022 Nov; 22(1):474. PubMed ID: 36348286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Lipoprotein(a) as a Residual Risk Factor in Long-Term Cardiovascular Outcomes in Patients With Acute Coronary Syndrome Treated With Statins.
    Takahashi D; Wada H; Ogita M; Yasuda K; Nishio R; Takeuchi M; Shitara J; Tsuboi S; Dohi T; Suwa S; Miyauchi K; Daida H; Minamino T
    Am J Cardiol; 2022 Apr; 168():11-16. PubMed ID: 35067346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis.
    Ezhov MV; Afanasieva OI; Il'ina LN; Safarova MS; Adamova IY; Matchin YG; Konovalov GA; Akchurin RS; Pokrovsky SN
    Atheroscler Suppl; 2017 Nov; 30():187-192. PubMed ID: 29096836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Lipoprotein(a) and Peri-procedural Myocardial Infarction in Patients With Diabetes Mellitus Who Underwent Percutaneous Coronary Intervention.
    Liu Y; Wang W; Song J; Zhang K; Xu B; Li P; Shao C; Yang M; Chen J; Tang YD
    Front Endocrinol (Lausanne); 2020; 11():603922. PubMed ID: 33613445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated Lipoprotein(a) as a potential residual risk factor associated with lipid-rich coronary atheroma in patients with type 2 diabetes and coronary artery disease on statin treatment: Insights from the REASSURE-NIRS registry.
    Nakamura H; Kataoka Y; Nicholls SJ; Puri R; Kitahara S; Murai K; Sawada K; Matama H; Iwai T; Honda S; Fujino M; Takagi K; Yoneda S; Otsuka F; Nishihira K; Asaumi Y; Tsujita K; Noguchi T
    Atherosclerosis; 2022 May; 349():183-189. PubMed ID: 35450750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Lipoprotein(a) on Long-Term (Mean 6.2 Years) Outcomes in Patients With Three-Vessel Coronary Artery Disease.
    Xu N; Jiang L; Xu L; Tian J; Zhang C; Zhao X; Feng X; Wang D; Zhang Y; Sun K; Xu J; Liu R; Xu B; Zhao W; Hui R; Gao R; Gao Z; Song L; Yuan J
    Am J Cardiol; 2020 Feb; 125(4):528-533. PubMed ID: 31864520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between lipoprotein(a) and long-term outcomes after percutaneous coronary intervention for lesions with in-stent restenosis.
    Zhang H; Zhang Y; Tian T; Wang T; Chen J; Yuan J; Qian J; Hu F; Dou K; Qiao S; Wu Y; Guan C; Xu B; Yang W; Song L
    J Clin Lipidol; 2023; 17(4):458-465. PubMed ID: 37248114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of LR11 as Residual Risk on Long-Term Clinical Outcomes in Patients with Coronary Artery Disease Treated with Statins after First Percutaneous Coronary Intervention.
    Suwa S; Ogita M; Takahashi N; Wada H; Dohi T; Kasai T; Okazaki S; Shimada K; Miyauchi K; Bujo H; Daida H
    Int Heart J; 2020 May; 61(3):470-475. PubMed ID: 32350212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of nutritional status assessed by the Controlling Nutritional Status score in patients with stable coronary artery disease undergoing percutaneous coronary intervention.
    Wada H; Dohi T; Miyauchi K; Doi S; Konishi H; Naito R; Tsuboi S; Ogita M; Kasai T; Okazaki S; Isoda K; Suwa S; Daida H
    Clin Res Cardiol; 2017 Nov; 106(11):875-883. PubMed ID: 28634674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention.
    Kardys I; Oemrawsingh RM; Kay IP; Jones GT; McCormick SP; Daemen J; Van Geuns RJ; Boersma E; Van Domburg RT; Serruys PW
    Clin Cardiol; 2012 Aug; 35(8):482-9. PubMed ID: 22488248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.